Age Related Macular Degeneration News and Research

RSS

Vision symptoms plus retinal changes trigger need for AMD intervention

An analysis of over 1000 individuals presenting with suspected exudative age-related macular degeneration has revealed which factors are most predictive of the need for treatment.

22 Aug 2012

Molecular Partners, Allergan to develop and commercialize DARPins against ophthalmic diseases

Allergan, Inc. and Molecular Partners AG today announced that they have significantly expanded their existing relationship by entering into two separate agreements to discover, develop, and commercialize proprietary therapeutic DARPin products for the treatment of serious ophthalmic diseases.

21 Aug 2012

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness

12 Aug 2012

Lucentis receives FDA approval for treatment of diabetic macular edema

The U.S. Food and Drug Administration today approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.

10 Aug 2012

Worldwide data reveal gaps in elderly eye care

Worldwide eye examination rates among older adults are very low, despite this age group being recommended to have an eye test at least every 1–2 years, say researchers from Canada.

10 Aug 2012

Planarian flatworms now a model system for studying eye development and eye diseases

Planarian flatworms have come under intense study for their renowned ability to regenerate any missing body part, even as adults. But now they may take on a starring role as a model system for studying eye development and eye diseases in vertebrates, including humans.

3 Aug 2012

Dosimetry data from SalutarisMD episcleral brachytherapy device clinical study on wet AMD

At the American Association of Physicists in Medicine (AAPM) Annual Meeting yesterday, Russell J. Hamilton, PhD, Professor and Physics Section Head, University of Arizona Department of Radiation Oncology, reviewed dosimetry data for a minimally invasive episcleral brachytherapy device developed by Salutaris Medical Devices, Inc. (SalutarisMD) to treat Wet AMD (Age-related Macular Degeneration), the leading cause of vision loss and blindness.

30 Jul 2012

ACT receives Australian patent for human retinal pigment epithelial cells

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued a patent in Australia, patent number 2005325753, "Improved modalities for the treatment of degenerative diseases of the retina."

28 Jul 2012

AAQ chemical temporarily restores vision in blind mice

A team of University of California, Berkeley, scientists in collaboration with researchers at the University of Munich and University of Washington in Seattle has discovered a chemical that temporarily restores some vision to blind mice, and is working on an improved compound that may someday allow people with degenerative blindness to see again.

26 Jul 2012

AHAF announces glaucoma and macular degeneration research grants

The American Health Assistance Foundation, a nonprofit organization with a history of funding breakthrough research on age-related vision diseases, announced today that it has awarded 21 new grants totaling $2.1 million to scientists worldwide who are studying glaucoma and macular degeneration. The two conditions are the leading causes of irreversible blindness in the world.

26 Jul 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2012 and provided an update on development programs.

25 Jul 2012

ACT treats fourth patient in U.S. clinical trial for Stargardt's Macular Dystrophy

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, today announced treatment of the fourth patient, the first in the second patient cohort, in its U.S. clinical trial for Stargardt's Macular Dystrophy (SMD).

13 Jul 2012

Nottingham researchers to lead Avastin clinical study for AMD

Nottingham researchers are leading a study to test the effectiveness of a controversial drug in the treatment of a common loss of vision.

12 Jul 2012

As needed ranibizumab effective for exudative AMD

Study findings suggest that ranibizumab significantly improves visual acuity in patients with exudative age-related macular degeneration when administered initially on a monthly basis and followed by re-treatment if needed.

10 Jul 2012

Cheaper drug to treat wet AMD increases risk of serious eye inflammation

A Queen's University study of two eye drugs used to treat wet Age-related Macular Degeneration (AMD) has determined the cheaper of the two could lead to eye inflammation, a potentially blinding adverse effect.

19 Jun 2012

Positive results from Salutaris’ episcleral brachytherapy trial on Wet AMD

Positive results from a trial of episcleral brachytherapy to treat Wet Age-related Macular Degeneration (Wet AMD) were presented today at the ARVO Drug and Gene Delivery to the Back of the Eye Conference.

15 Jun 2012

Ophthotech’s Fovista anti-PDGF combination therapy superior to Lucentis for wet AMD

Ophthotech Corporation today announced results from the first clinical trial to show statistically significant superior efficacy over Lucentis (ranibizumab) monotherapy for the treatment of neovascular age-related macular degeneration (wet AMD).

14 Jun 2012

VisionCare expands CentraSight telescope implant provider teams

VisionCare Ophthalmic Technologies, Inc., developer of the first FDA-approved ophthalmic telescope implant indicated to improve vision in patients with end-stage age-related macular degeneration (AMD), announced today the expansion of its CentraSight™ provider teams nationwide.

8 Jun 2012

DHA prevents age-related vision loss in lab tests

An omega-3 fatty acid found in fish, known as DHA, prevented age-related vision loss in lab tests, demonstrates recently published medical research from the University of Alberta.

31 May 2012

Study examines effects of UV-blocking contact lenses on macular pigment density

Blocking the transmission of ultraviolet light (UV) through a contact lens may have an effect in maintaining the eye's macular pigment density, according to new research presented today at the 2012 British Contact Lens Association Clinical Conference. Existing research suggests that a higher level of macular pigment appears to have a protective effect against age-related macular degeneration, a major cause of severe vision loss for people over the age of 55.

25 May 2012